- Conditions
- Heart Failure, Worsening Heart Failure (WHF)
- Interventions
- Placebo, R2R01
- Drug
- Lead sponsor
- River 2 Renal Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 8
- States / cities
- Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 78 Years
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Duarte, California • Denver, Colorado + 23 more
- Conditions
- Hepatitis C
- Interventions
- ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
- Conditions
- Type I Diabetes
- Interventions
- NNC0361-0041, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 16
- States / cities
- Orange, California • San Francisco, California • Stanford, California + 13 more
- Conditions
- Embolism, Thrombosis
- Interventions
- Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux sodium), Avidin, Placebo (for warfarin), Enoxaparin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
- Interventions
- Denosumab Inj 60 mg/ml, Placebo
- Drug · Other
- Lead sponsor
- Thomas Nickolas, MD MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Evanston, Illinois • New York, New York
- Conditions
- Obesity, Overweight, Overweight With One Weight Related Comorbidity
- Interventions
- RO7204239, RO7204239 Matching Placebo, Tirzepatide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 19
- States / cities
- Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more
- Conditions
- Autoimmune Hepatitis
- Interventions
- zetomipzomib, placebo, zetomipzomib in open-label extension
- Drug
- Lead sponsor
- Kezar Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Los Angeles, California • Redwood City, California + 17 more
- Conditions
- Herpes Zoster, HIV Infections
- Interventions
- ZOSTAVAX, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2428757, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 15
- States / cities
- Bermuda Dunes, California • Chula Vista, California • Huntington Beach, California + 12 more
- Conditions
- Indolent Systemic Mastocytosis
- Interventions
- sarilumab, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Placebo, Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 17 more
- Conditions
- Moderate or Severe Submental Fullness
- Interventions
- Deoxycholic acid injection, Placebo
- Drug
- Lead sponsor
- Kythera Biopharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 506 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Irvine, California + 24 more
- Conditions
- Schwannomatosis, Schwannomas, Pain, Chronic
- Interventions
- Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Psoriasis
- Interventions
- CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg), CNTO 1959 (100 mg), CNTO 1959 (200 mg), Adalimumab, Placebo
- Drug
- Lead sponsor
- Janssen Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 15 more
- Conditions
- Sleep Restriction
- Interventions
- Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
- Drug
- Lead sponsor
- Peter y. Liu
- Other
- Eligibility
- 22 Years to 45 Years · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction
- Interventions
- LY3540378, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Covina, California • Northridge, California + 18 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w
- Drug
- Lead sponsor
- R-Pharm International, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,648 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 64
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Omalizumab Injection, Xolair Prefilled Syringe
- Drug
- Lead sponsor
- Kashiv BioSciences, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Brandon, Florida • Brooksville, Florida • Miami Lakes, Florida + 1 more
- Conditions
- Arthritis, Rheumatoid
- Interventions
- GSK3196165 (Otilimab), Tofacitinib, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,764 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 64
- States / cities
- Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more
- Conditions
- Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
- Interventions
- Xembify, Placebo
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 9
- States / cities
- Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more
- Conditions
- Eosinophilic Oesophagitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more